Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism

Oncotarget

Volumn 4, Issue 6, 2013, Pages 911-922

  Sola, Brigitte ^a   Poirot, Marc ^b,c,d   De Medina, Philippe ^b,e   Bustany, Sophie ^a   Marsaud, Véronique ^f   Silvente Poirot, Sandrine ^b,c,d   Renoir, Jack Michel ^g  

^a UNIVERSITÉ DE CAEN   (France)

^b CANCER RESEARCH CENTER OF TOULOUSE   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e Affichem   (France)

^f Centre National de la Recherche Scientifique   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Apoptosis; Autophagy; Cholesterol metabolism; Multiple myeloma; Tamoxifen

Indexed keywords

1 BENZYL 4 (N 2 PYRROLIDINYLETHOXY)BENZENE; 11 [4 (2 DIMETHYLAMINOETHOXY)PHENYL]ESTRADIOL; 11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; AFIMOXIFENE; ANTIESTROGEN; BAFILOMYCIN; BAFILOMYCIN A1; CASPASE; CHOLESTEROL; CHOLESTEROL 5,6 EPOXIDE HYDROLASE; DANSYLCADAVERINE; DESMOSTEROL; DEXAMETHASONE; EPOXIDE HYDROLASE; GLUCOSE; LIGAND; MAMMALIAN TARGET OF RAPAMYCIN; MICROTUBULE ASSOCIATED PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTIMYELOMA ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BINDING SITE; CHOLESTEROL METABOLISM; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE METABOLISM; HUMAN; LIGHT CHAIN; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

APOPTOSIS; AUTOPHAGY; BINDING SITES; CELL LINE, TUMOR; CHOLESTEROL; ESTROGEN RECEPTOR MODULATORS; HUMANS; LIGANDS; MULTIPLE MYELOMA;

EID: 84880836872     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1066     Document Type: Article

References (47)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG and Anderson KC. Multiple myeloma. Lancet. 2009; 374(9686): 324-339.
2. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG and Anderson KC. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012; 9(3): 135-143.
3. Treon SP, Teoh G, Urashima M, Ogata A, Chauhan D, Webb IJ, and Anderson KC. Anti-estrogens induce apoptosis of multiple myeloma cells. Blood. 1998; 92(5): 1749-1457.
4. Otsuki T, Yamada O, Kurebayashi J, Moriya T, Sakaguchi H, Kunisue H, Yata K, Uno M, Yawata Y and Ueki A. Estrogen receptors in human myeloma cells. Cancer Res. 2000; 60(5): 1434-1441.
5. Gauduchon J, Gouilleux F, Maillard S, Marsaud V, Renoir JM, and Sola B. 4-hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through the downregulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members. Clin Cancer Res. 2005; 11(6): 2345-2354.
6. Olivier S, Close P, Castermans E, de Leval L, Tabruyn S, Chariot A, Malaise M, Merville MP, Bours V and Franchimont N. Raloxifen-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature. Mol Pharmacol. 2006; 69(5): 1615- 1623.
7. Gauduchon J, Seguin A, Marsaud V, Clay D, Renoir JM and Sola B. Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-caspases. Int J Cancer. 2008; 122(9): 2130-2141.
8. Urbinati G, Audisio D, Marsaud V, Plassat V, Arpicco S, Sola B, Fattal E and Renoir JM. Therapeutic potential of new 4-hydroxy-tamoxifen loaded pH-gradient liposomes in a multiple myeloma experimental model. Pharm Res. 2010; 27(2): 327-339.
9. Maillard S, Gauduchon J, Gouilleux F, Gougelet A, Marsaud V, Connault E, Opolon P, Fattal E, Sola B and Renoir JM. Improved antitumoral properties of pure antiestrogen RU 58668-loaded liposomes in multiple myeloma. J Steroid Biochem Mol Biol. 2006; 100(1-3): 67- 78.
10. McDonnell DP and Wardell SE. The molecular mechanisms underlying the pharmacological actions of ER modulators: Implications for new drug discovery in breast cancers. Curr Opin Pharmacol. 2010; 10(6): 620-628.
11. Kedjouar B, de Medina P, Oulad-Abdelghani M, Payré B, Silvente-Poirot S, Favre G, Faya JC and Poirot M. Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem. 2004; 279(32): 34048-34061.
12. de Medina P, Paillasse RP, Segala G, Poirot M and Silvente-Poirot S. Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target of tamoxifen and AEBS ligands. Proc Natl Acad Sci USA. 2010; 107(33): 13520-13525.
13. Silvente-Poirot S and Poirot M. Cholesterol epoxide hydrolase and cancer. Curr Opin Pharmacol. 2012; 12(6): 696-703.
14. de Medina P, Payré B, Boubekeur N, Bertrand-Michel J, Tercé F, Silvente-Poirot S and Poirot M. Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells. Cell Death Differ. 2009; 16(10): 1372-1384.
15. Hoang B, Benavides A, Shi Y, Frost P and Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther. 2009; 8(7): 1974-1984.
16. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Different. 2012; 19(1): 107-120.
17. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8(4): 445-544.
18. Segala G, de Medina P, Iuliono L, Zerbinati C, Paillasse MR, Noguer E, Dalenc F, Payré B, Jordan VC, Record M, Silvente-Poirot S and Poirot M. 5,6-epoxy-cholesterols contribute to the anticancer pharmacology of tamoxifen in breast cancer cells. Biochem Pharmacol. 2013 March 7. doi:pii: S0006-2952(13)00154-8. 10.1016/j. bcp.2013.02.031.
19. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC et al. Dual inhibition of Akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010; 9(4): 963-975.
20. Palacios C, Martín-Pérez R, López-Pérez AI, Pandiella A and López-Rivas A. Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminotheylamino-17-demethoxygeldanamycin-induced apoptosis. Leuk Res. 2010; 34(11): 1533-1538.
21. Puissant A, Robert G and Auberger P. Targeting autophagy to fight hematopoietic malignancies. Cell Cycle. 2010; 9(17): 3470-3478.
22. Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N and Anderson KC. Targeting NDA+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signalregulated kinase (ERK1/2) inhibition. Blood. 2012; 120(17): 3519-3529.
23. Pene F, Claessens YE, Muller O, Viguié F, Mayeux P, Dreyfus F, Lacombe C and Bouscary D. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002; 21(43): 6587-6597.
24. Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer. 2007; 7(1): 46-53.
25. Musgrove EA and Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009; 9(9): 631-643.
26. Renoir JM, Marsaud V and Lazennec G. Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem Pharmacol. 2013; 85(4): 449-465.
27. Michallet AS, Mondiere P, Taillardet M, Leverrier Y, Genestier L and Defrance T. Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma. PLoS ONE. 2011; 6(10): e25820.
28. Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C and Johnson DE. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy. 2012; 8(12): 1873-1874.
29. Shanmugam M, McBrayer SK, Qian J, Raikoff K, Avram MJ, Singhal S, Gandhi V, Schumacker PT, Krett NL and Rosen ST. Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminodaenosine. J Biol Chem. 2009; 284(39): 26816-26830.
30. Pan Y, Gao Y, Chen L, Gao G, Dong H, Yang Y, Dong B and Chen X. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin Cancer Res. 2011; 17(10): 3248-3258.
31. Puissant A, Robert G and Auberger P. Targeting autophagy to fight hematopoietic malignancies. Cell Cycle. 2010; 9(17): 3470-3478.
32. Crawford AC, Riggins RB, Shajahan AN, Zwart A and Clarke R. Co-inibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis. PLoS ONE. 2010; 5(1): e8604.
33. Moreaux J, Klein B, Bataille R, Descamps G, Maïga S, Hose D, Goldschmidt H, Jauch A, Rème T, Jourdan M, Amiot M and Pellat-Deceunynck C. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cells. Haematologica. 2011; 96(4): 574-582.
34. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009; 23(12): 2210-2221.
35. Schmidlin H, Diehl SA and Blom B. New insights into the regulation of human B-cell differentiation. Trends Immunol. 2009; 30(6): 277-285.
36. Silvente-Poirot S and Poirot M. Cholesterol epoxide hydrolase and cancer. Curr Opin Pharmacol. 2012; 12(6): 696-703.
37. Berrodin TJ, Shen Q, Quinet EM, Yudt MR, Freedman LP and Nagpal S. Identification of 5a,6a-epoxycholesterol as a novel modulator of liver X receptor activity. Mol Pharmacol. 2010; 78(6): 1046-1058.
38. Vedin LL, Lewandowski SA, Parini P, Gustafsson JA and Steffensen KR. The oxysterol receptor LXR inhibits proliferation of human breast cancer. Carcinogenesis 2009; 30(4): 575-579.
39. Gutiérrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Fermiñán E, Arcos MJ, Sánchez ML, Hernández JM and San Miguel JF. Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007; 21(3): 541-549.
40. Storch J and Xu Z. Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking. Biochim Biophys Acta 2009; 1791(7): 671-678.
41. Peake KB and Vance JE. Defective cholesterol trafficking in Niemann-Pick C-deficient cells. FEBS Lett 2010; 584(13): 2731-2739.
42. Liu K and Czaja MJ. Regulation of lipid stores and metabolism by lipophagy. Cell Death Different. 2013; 20(1): 3-11.
43. Laplante M and Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr Biol. 2009; 19(22): R1046-R1052.
44. Ricoult SJH and Manning BD. The multifaceted role of mTORC1 in the control of lipid metabolism. EMBO Rep. 2013; 14(3): 242-251.
45. Poirot M, de Medina P, Delarue F, Perie JJ, Klaebe A and Faye JC. Synthesis, binding and structure-affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS). Bioorg Med Chem. 2000; 8(8): 2007-2016.
46. Petiot A, Ogier-Denis E, Blommaart EF, Meijer AJ and Codogno P. Distinct classes of phosphatidylinositol 3'-kinase are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem. 2000; 275(2): 992-998.
47. Payré B, de Medina P, Boubekeur N, Mhamdi L, Bertrand-Michel J, Tercé F, Fourquaux I, Goudounèche D, Record M and Poirot M. Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Mol Cancer Ther 2008; 7(12): 3707-3718